All News

2020

September

Media Release / Sep 23, 2020

Novartis Provides Update on AVXS-101 Intrathecal Clinical Development Program

Read More
Media Release / Sep 21, 2020

Novartis Kisqali® receives the highest rating of any CDK4/6 inhibitor on the ESMO Magnitude of Clinical Benefit Scale

Read More
Media Release / Sep 19, 2020

Novartis Piqray® data show survival benefit for patients with HR+/HER2- advanced breast cancer with a PIK3CA mutation

Read More
Media Release / Sep 19, 2020

Novartis reports late-breaking data from Phase III COMBI-i trial of spartalizumab (PDR001) with Tafinlar® and Mekinist® in advanced melanoma

Read More
Media Release / Sep 16, 2020

Novartis Tafinlar® + Mekinist® demonstrates long-term, relapse-free survival benefit for high-risk, stage III melanoma patients in study published in NEJM

Read More
Media Release / Sep 16, 2020

Novartis reinforces commitment to patient access, pricing a EUR 1.85 billion sustainability-linked bond

Read More
Media Release / Sep 14, 2020

European Medicines Agency (EMA) approves safety label update for Novartis Beovu®

Read More
Media Release / Sep 14, 2020

Novartis reports positive topline results from the first Phase III trial of Beovu® versus aflibercept in patients with diabetic macular edema (DME)

Read More
Media Release / Sep 11, 2020

Novartis data show early treatment with Mayzent® (siponimod) delays disability progression and show benefits in cognitive performance in patients with secondary progressive multiple sclerosis (SPMS)

Read More
Media Release / Sep 11, 2020

Novartis presents data at ACTRIMS-ECTRIMS for Kesimpta® (ofatumumab) in newly diagnosed treatment-naïve adults with relapsing multiple sclerosis

Read More

Related Links

Novartis Annual Reporting Suite

Read and download the Annual Review, the Annual Report and Form 20-F, and the Novartis in Society ESG report.

Learn More